logo-loader
ImmuPharma PLC

Technology review published-Nature Communications

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .br{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 53.95pt 90.0pt;}div.br{}p.dm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.dk{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.dn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}span.di{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.do{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.dp{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.dq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; line-height: 15.0pt; punctuation-wrap: hanging; text-align: center; text-autospace: ideograph-numeric ideograph-other}p.dr{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white} span.dd{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.ds{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:15.0pt;text-align:justify;line-height: 14.65pt;background:white}span.db{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.dt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: justify}p.du{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-div: italic; text-align: justify}span.dv{color:blue;text-decoration:underline;font-size:11.0pt;font-family:"Calibri","sans-serif";letter-spacing:.15pt}table.dw{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.ci{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.dx{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.dy{width:18.0cm;border-collapse:collapse} td.cu{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.dz{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.cs{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.ct{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.cr{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.ea{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}span.cp{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.eb{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.ec{color:blue;font-size:11.0pt;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.ed{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify} td.cl{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ck{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";}table.ee{width:453.75pt;border-collapse:collapse}td.cc{width:428.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.ef{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-bottom: 10.5pt; punctuation-wrap: hanging; text-autospace: ideograph-numeric ideograph-other}span.ch{font-size:11.0pt;font-family:"Calibri","sans-serif";color:#222222; letter-spacing:.15pt}p.eg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:21.0pt;punctuation-wrap: hanging;text-autospace:ideograph-numeric ideograph-other}.cf{font-div: italic}span.ce{font-size:11.0pt;font-family: "Calibri","sans-serif";letter-spacing:.15pt} td.cb{width:3.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ca{width:343.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.bz{width:88.55pt;padding:0cm 5.4pt 0cm 5.4pt}td.by{width:79.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.bv{width:456.8pt;padding:0cm 5.4pt 0cm 5.4pt}p.eh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-157.35pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}td.bu{border:none}span.ei{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none} /**/
RNS Number : 0641R
Immupharma PLC
26 February 2019
 

 

RNS REACH                                                                                                                                             26 February 2019

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Technology review published in Nature Communications

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal 'Nature Communications' published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl ("Ureka"), ImmuPharma's subsidiary.

 

Ureka, based at the IECB in Bordeaux, France, is carrying out research into novel peptide molecules to generate drug candidates for many diseases.  The publication describes for the first time the unique properties of oligourea foldamers as a tool to improve the pharmaceutical properties of peptides. Further improvements not yet described here are related to more focused medical indications. One of the first focus areas has been GLP-1 analogues for the treatment of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as  proof of concept for Ureka's technology.

Further applications of the Urelix™ technology include protein/protein interactions, notably in cancer, and improvement of marketed efficacious peptides allowing additional long lasting patent protection, paving the way for a life cycle management franchise.  Novel patented technologies are also currently implemented to cover other aspects of the improvement of peptides including potential oral delivery.

 

The publication was entitled: "Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo" and was authored by a number of researchers working within Ureka including Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer and Dr Sébastien R. Goudreau, Head of Research at Ureka. 

Introduction to the Publication

Peptides have gained so much attention in the last decade that they are now part of the main strategies, with small molecules and biologics, for developing new medicines. Despite substantial progress, the successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability.

 

Commenting, Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer, said: "I am very proud of the achievement of the research team in Ureka since it started in 2014, having built a team of skilled people and expanded our collaboration with the CNRS, developing an exciting technology backed by a strong patent portfolio. As such, a pleasing validation of years of research by our scientific team and collaborators, giving us further confidence in the long term potential of our Ureka platform."

 

Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said: "Natural peptides play key roles in human biological processes and are effective and selective signaling molecules that bind to specific receptors on cells.  Using natural peptides as drugs is not so effective because they are  quickly broken down.  To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs. The global peptide therapeutics market achieved sales of $30 billion in 2018."

 

The full paper can now be downloaded from: http://dx.doi.org/10.1038/s41467-019-08793-y or accessed via Nature Communications website: https://www.nature.com/search?q=immupharma.

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 

 

 

About Nature Communications

Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences.  Papers published by the journal represent important advances of significance to specialists within each field.  For more information go to: https://www.nature.com

About the IECB

The Institut Européen de Chimie et Biologie (European Institute of Chemistry and Biology) is an international and interdisciplinary research team incubator, placed under the joint authority of the CNRS, Inserm and the University of Bordeaux.  The CNRS is a public organization under the responsibility of the French Ministry of Education and Research.  The CNRS is top of the Nature Index (The Nature Index ranks publication productivity and is one indicator of global high-quality research output ) and has over 31,000 staff and €3.2 bn annual budget. 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRASEAFWIFUSEFE

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £16.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability. McCarthy says the six month extension study confirmed its outstanding and robust...

on 4/7/19